DKK1 - Dkk1 dickkopf WNT signaling pathway inhibitor 1 Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 293897

Summary

Predicted to enable co-receptor binding activity; low-density lipoprotein particle receptor binding activity; and receptor antagonist activity. Involved in negative regulation of ossification and positive regulation of neuron death. Located in extracellular space. Used to study visual epilepsy. Human ortholog(s) of this gene implicated in anodontia. Orthologous to human DKK1 (dickkopf Wnt signaling pathway inhibitor 1). [provided by Alliance of Genome Resources, Apr 2022]

DKK1 Products (1)

mRNA Protein Name
NM_001106350.1 NP_001099820.1 dickkopf-related protein 1 precursor

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence References Source
involved in negative regulation of ossification IMP
IMP: Inferred from mutant phenotype
21773994 RGD
Cellular Component GO Annotation Evidence References Source
located in extracellular space IDA
IDA: Inferred from direct assay
22009597 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

dickkopf-related protein 1

  • dickkopf 1 homolog

  • dickkopf homolog 1

  • dickkopf-like protein 1

Recombinant DKK1 Proteins

Cat. No. Product Name Accession Purity
HY-P73305 DKK-1 Protein, Rat (HEK293, His, solution) A6I0Z0/NP_001099820.1 (T32-H270) ≥ 95%, as determined by reducing SDS-PAGE.
HY-P73305A DKK-1 Protein, Rat (HEK293, His) A6I0Z0/NP_001099820.1 (T32-H270) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-14930A Mirodenafil dihydrochloride 99.11% Unkown
HY-14930 Mirodenafil 99.88% Unkown

Clinical Phase

Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Phase
HY-P99906 Sirexatamab 99.84% Phase 2

Pre-clinical Phase

Bioactive Molecules (12)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-11035 WAY-262611 99.96% Unkown
HY-D0961 Gallocyanine chloride Activator 92.00% Unkown
HY-N5124 Meloside A Inhibitor 98.72% Unkown
HY-N2276 Nodakenetin Activator 99.66% Unkown
HY-RS03787 DKK1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-14930S Mirodenafil-d7 / Unkown
HY-162970 XD23 Activator / Unkown
HY-175219 CA-II/Dkk1-IN-1 Inhibitor / Unkown
HY-W185542 E09241 / Unkown
HY-124841 Gallocyanine / Unkown
HY-RS16543 Dkk1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS22975 Dkk1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (2)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P992113 Evabosmig Activator / Unkown
HY-P991569 PF-04840082 Antagonist / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens DKK1 NCBI NCBI:22943